Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
netFormulary
Home
Treatment Use
Class
Chapters
News
Reports
Contact
SEARCH
Searching for :
Ustekinumab
Open monograph to display formulary status.
Formulary items found
Status
Description
Section
RED
Ustekinumab 45mg, 90mg Pyzchiva
®
Wezenla
®
(Pre-filled syringe)
Musculoskeletal and joint diseases, Cytokine modulators, 10.01.03
RED
Ustekinumab 45mg, 90mg Pyzchiva
®
Wezenla
®
(Pre-filled syringe or injection)
Skin, Drugs affecting the immune response, 13.05.03
RED
Ustekinumab 45mg, 90mg, 130mg Pyzchiva
®
Wezenla
®
(Pre-filled syringe, vials or IV infusion)
Gastro-intestinal system, Drugs affecting the immune response, 01.05.03
Links found
MHRA Drug Safety Update (January 2015) - Ustekinumab (Stelara): risk of exfoliative dermatitis
NICE TA 633 Ustekinumab for treating moderately to severely active ulcerative colitis
NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
NICE TA456:Ustekinumab for moderately to severely active Crohn’s disease after previous treatment